We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 16, 2020

Vemurafenib Effective in NSCLC With BRAF-V600 Mutations but Not BRAF non-V600 Mutations

Annals of Oncology


Additional Info

Annals of Oncology
Vemurafenib in Non-Small-Cell Lung Cancer Patients With BRAFV600 and BRAF nonV600 Mutations
Ann. Oncol 2020 Jan 06;[EPub Ahead of Print], J Mazières, C Cropet, L Montané, et al

Further Reading